David Dworaczyk, PhD: Utuly, a Non-needle Epinephrine Alternative Patients are Waiting for
There have been long stretches of time between the innovation of epinephrine delivery in the allergy space.
Source: hcplive.com
David Dworaczyk News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from David Dworaczyk. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In David Dworaczyk Today - Breaking & Trending Today
Fighting anaphylaxis without needles: Raleigh pharma startup raises $15M
Bryn Pharma, a privately held pharmaceutical company focused on creating a new treatment for anaphylaxis - a life-threatening allergic reaction - not only has a new CEO and COO but also $15 million in cash as the company seeks FDA approval for its unique nasal spray.
Source: wraltechwire.com
David Dworaczyk, PhD: FDA Review is Anticipated for an Epinephrine Nasal Spray
Bryn Pharma is planning to submit the New Drug Application for Utuly this year and expects to receive approval early next year.
Source: hcplive.com
David Dworaczyk, PhD, Shares New Data on Nasal Epinephrine for Anaphylaxis
Data presented at the American Society for Clinical Pharmacology and Therapeutics annual meeting show promise for Utuly, a novel intranasal epinephrine spray for treating anaphylaxis.
Source: hcplive.com
Raleigh-based Bryn Pharma adds COO to join new CEO leadership team
Bryn Pharma has appointed a new Chief Operating Officer, the company announced this week. This announcement comes just two weeks after the Raleigh-based startup named a new CEO.
Source: wraltechwire.com